%0 Journal Article
%T OCT生物标志物与DME患者抗VEGF治疗预后的相关性<br>Correlation between OCT Biomarkers and Prognosis of Anti-VEGF Therapy in Patients with DME
%A 文丹丹
%A 王理论
%J Advances in Clinical Medicine
%P 5093-5099
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.134722
%X 糖尿病黄斑水肿(DME)在全球范围内严重威胁患者视力。抗VEGF治疗是目前DME的一线治疗方式，部分患者对这一治疗方式反应较差，有研究发现，某些OCT生物标志物与抗VEGF治疗不应答有一定的相关性。本文从DME的发病机制，抗VEGF治疗原理及OCT生物标志物与抗VEGF治疗的相关性展开描述，分析DME患者的OCT特征，指导诊断及治疗。<br />
Diabetic macular edema (DME) is a serious threat to visual acuity worldwide. Anti-VEGF therapy is the current first-line treatment for DME, and some patients have poor response to this treatment. Some studies have found that some OCT biomarkers are associated with non-response to anti-VEGF therapy. In this paper, the pathogenesis of DME, the principle of anti-VEGF therapy and the correla-tion between OCT biomarkers and anti-VEGF therapy were described, and the OCT features of DME patients were analyzed to guide diagnosis and treatment.
%K 糖尿病黄斑水肿，OCT生物标志物，抗VEGF治疗<br>Diabetic Macular Edema
%K OCT Biomarker
%K Anti-VEGF Therapy
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=63650